Please provide your email address to receive an email when new articles are posted on . More than a quarter of patients sampled who had Staphylococcus aureus bacteremia did not receive adequate ...

Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...

This article was originally published on Dermatology Times. This version has been lightly edited. The pathogen Staphylococcus aureus often invades the inflamed skin of people with atopic dermatitis ...

A new class of engineered proteins may counter infection caused by Staphylococcus aureus - a bacterial species considered one of the largest global health threats, a new study suggests. Published ...

Linezolid Nosocomial pneumonia, cSSSI Oral and intravenous form available, bacteriostatic, not approved for catheter-related bloodstream infections, side effects include myelosuppression, ...

The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry has valued at US$ 3.9 billion in 2022 and is anticipated to grow to US$ 5.5 billion by 2030, with sales revenue set to ...

Rising investments in the biopharmaceutical industry in response the coronavirus pandemic, has generated new opportunities for the methicillin-resistant staphylococcus aureus treatment market.

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for ...

Cumberland Pharmaceuticals CPIX has expanded the international footprint of its antibiotic therapy Vibativ (telavancin) with its official launch in China. The move follows regulatory approval from ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...